Jul 29, 2025 7:35am EDT Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy
Jul 18, 2025 4:15pm EDT Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
Mar 18, 2025 7:30am EDT Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
Mar 13, 2025 7:30am EDT Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
Feb 25, 2025 7:00am EST Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy
Dec 10, 2024 7:30am EST Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland
Oct 23, 2024 7:30am EDT Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland
Sep 16, 2024 8:30am EDT Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.
